Gelatin Market 2026: Key Trends Every Food Manufacturer Should Know

Gelatin is having a complicated moment. On one hand, demand is rising: pharmaceutical capsule manufacturing is expanding, functional gummy production has entered a multi-year growth phase, and the collagen supplement boom is pulling gelatin into health and wellness categories it barely occupied a decade ago. On the other hand, every ingredient buyer now fields internal questions about animal-derived inputs, sustainability credentials, and whether plant-based alternatives have finally closed the performance gap.

For food manufacturers making sourcing and formulation decisions in 2026, the market picture matters. This article draws on published market research, industry data, and regulatory developments to give you a grounded view of where gelatin demand is heading — what is driving it, how porcine and bovine sources are competing, what clean-label pressure actually means for gelatin in practice, and what the European supply picture looks like heading into 2027.

The Gelatin Market in 2026: A Snapshot

Before examining the trends, a note on the data: gelatin market size estimates vary dramatically across research publications, primarily because different reports draw the scope boundary in different places — some include hydrolysed collagen and collagen peptides (a much larger category), others cover gelatin narrowly. The variance between reports runs from a few billion dollars to over $20 billion projected by 2034, depending on scope.

The most useful anchor is volume, which is less susceptible to definitional inflation. Global gelatin production volume was estimated at approximately 441,000–471,000 tonnes in 2024 (ChemAnalyst; IMARC Group). For value, the most frequently cited mid-range figure for gelatin in the conventional sense — excluding hydrolysed collagen — sits between $3.6 billion and $4.0 billion in 2024, with CAGR projections of 5.5–7.3% through 2030–2032 (Expert Market Research; Intel Market Research). Reports citing higher values ($7–8 billion) typically encompass collagen peptides and related products — a useful distinction to keep in mind when evaluating any market report.

What is consistent across virtually all sources: Europe is the largest consuming region, accounting for 38–41% of global gelatin demand. The continent's established pharmaceutical manufacturing base, its large confectionery and dairy sectors, and its increasingly stringent clean-label and traceability requirements all contribute to that dominance.

What Is Driving Gelatin Demand in 2026

Pharmaceutical capsules: the most reliable growth engine

The pharmaceutical segment is the most structurally stable demand driver in the gelatin market. Hard and soft gelatin capsule production cannot easily substitute gelatin without significant reformulation — capsule dissolution profiles, physical handling properties, and regulatory documentation are all built around gelatin's specific characteristics. The pharmaceutical gelatin market was valued at approximately $1.3–1.7 billion in 2023–2024 (GM Insights; SNS Insider), with CAGR projections of 5.5–5.8% through 2034 — a growth rate driven by ageing populations in Europe and North America, expanded chronic disease treatment volumes, and the continued OTC supplement market expansion.

Porcine Type A gelatin is particularly suited to softgel capsule manufacturing, where its higher clarity, quicker gelation, and strong gelling strength are operationally valuable. Several market sources note that porcine gelatin held approximately 47% of the pharmaceutical gelatin segment in 2023 (SNS Insider), maintaining a stable position despite religious or dietary restriction-driven demand for alternatives in certain markets.

For food manufacturers who also produce nutraceutical products — gummies, softgel supplements, protein-enriched tablets — the same supplier and specification requirements apply. Brodnica's pharmaceutical gelatin is produced under BRCGS Grade AA and ISO 22000 systems, providing the documentation depth pharmaceutical and nutraceutical buyers require.

Nutraceutical gummies: the fastest-growing food application

The gummy nutraceutical category has been one of the most consistent growth stories in food-adjacent gelatin demand over the past three years. Gummies require high Bloom strength gelatin for texture stability, quick setting, and clean flavour neutrality — properties that gelatin provides more reliably than plant-based alternatives under standard industrial confectionery production conditions.

Pectin-based vegan gummies have improved considerably, but they set differently under heat and acidic conditions, and their production parameters differ enough from gelatin-based gummies that most manufacturers treat them as separate product lines rather than a direct substitution. For gelatin-based gummy production, the supply and specification question therefore remains active and growing.

The collagen-gelatin halo effect

Consumer awareness of collagen peptide supplements — driven by social media, the beauty-from-within category, and joint health claims — has created a positive contextual frame for gelatin. Gelatin and hydrolysed collagen share the same raw material origin; gelatin's positioning as a "natural protein from collagen" benefits from the broader collagen wellness narrative even when the specific end product is not a supplement. This is not a direct demand driver for food-grade gelatin, but it softens the "animal-derived" objection among health-conscious consumers and creates narrative space for transparent gelatin use in functional food labelling.

Porcine vs Bovine Gelatin: Which Source Is Gaining Ground?

Type A's durable dominance

Porcine (Type A) gelatin accounts for approximately 52–57% of the global gelatin market by volume (Fortune Business Insights; Coherent Market Insights), a position that has held stable and, by most accounts, is strengthening in European and pharmaceutical applications. The functional advantages are real: compared to bovine (Type B) gelatin, porcine gelatin typically achieves higher Bloom strength values, produces clearer gels, has a lower ash content, and has a shorter extraction cycle — advantages that matter in confectionery, pharmaceutical capsule shell production, and high-clarity dessert applications.

In Europe specifically, porcine gelatin benefits from a geographically concentrated, auditable raw material supply chain. Poland, Germany, France, and Spain all have significant pork production infrastructure, enabling shorter farm-to-factory chains and simpler traceability documentation — both increasingly valued by procurement teams operating under ESG and supply security frameworks. 

Where bovine gelatin holds its position 

Bovine gelatin retains structural advantages in two areas. First, halal and kosher market segments: in Muslim-majority markets (Middle East, GCC, parts of Southeast Asia) and Jewish market segments, porcine gelatin is excluded by religious dietary law, making bovine or fish gelatin the only animal-derived options. Second, certain pharmaceutical applications where established regulatory documentation specifies bovine sources — changing these requires reformulation work and regulatory submission updates.

One friction point for bovine gelatin procurement: BSE/TSE documentation requirements are more complex for bovine-derived gelatin than porcine, because bovine animals carry a higher regulatory risk classification under EU Regulation (EC) No 999/2001. For European pharmaceutical buyers, this translates into additional documentation burden — a structural factor that has incrementally favoured porcine sourcing in pharmaceutical excipient qualification processes.

Plant-based alternatives: improving but not yet structurally competitive

Pectin, carrageenan, agar, and methylcellulose are genuine alternatives for specific applications — and for products specifically targeting vegan or vegetarian consumers, they are the correct choice. That is worth stating clearly.

However, for industrial-scale confectionery gelling, pharmaceutical capsule manufacturing, and formulations requiring gelatin's characteristic thermoreversible gel structure and Bloom-grade consistency across production batches, plant-based alternatives do not yet consistently replicate the performance profile. HPMC (hydroxypropyl methylcellulose) is the most advanced pharmaceutical capsule alternative — it has established regulatory documentation and can achieve equivalent dissolution profiles in specific formulation scenarios — but it commands a significant cost premium and has not displaced gelatin at scale in hard capsule manufacturing.

The honest assessment: plant-based gelling agents are an important and growing category, serving segments that animal-derived gelatin cannot. They are not yet, in 2026, a structural threat to gelatin's dominant position in its core applications.

Clean-Label and Sustainability Pressure: How Gelatin Responds

The clean-label case for gelatin

Gelatin occupies a genuinely advantageous position in the clean-label landscape. Under EU Regulation (EC) No 1333/2008 on food additives, gelatin is not classified as a food additive. It carries no E-number. It appears on ingredient declarations simply as "gelatin" — a single-word, immediately recognisable, natural protein. This is confirmed both by EU food law and by industry sources including Rousselot, one of the world's largest gelatin producers.

In practical clean-label terms: gelatin is non-GMO, minimally processed (partial hydrolysis of natural collagen), and derived from a single source. For food manufacturers navigating retailer clean-label standards and ingredient transparency demands, gelatin is legitimately easy to defend — as long as origin communication is clear and the supplier can provide full traceability documentation.

The only clean-label complication is the animal-origin question. For mainstream (non-vegan) food categories, this is increasingly managed through transparent labelling rather than avoidance — communicating natural origin clearly rather than removing the ingredient.

The circular economy argument

Gelatin production is structurally a circular economy activity. It converts pork skin and bones — by-products of meat production that would otherwise become waste — into a high-value food and pharmaceutical ingredient. For procurement teams building supplier sustainability arguments under EU Corporate Sustainability Reporting Directive (CSRD) — in force since January 2024 — and Corporate Sustainability Due Diligence Directive (CSDDD), published in July 2024 with phased application from 2027 onwards, the by-product valorisation narrative is factually sound and increasingly documentable.

Gelatin production does carry an energy and water processing footprint, and this should not be overstated. But on the specific metric of ingredient origin sustainability — turning a waste by-product into a functional ingredient — gelatin's position is genuinely strong and aligns with EU Farm-to-Fork strategy principles on reducing food chain waste.

European Market Focus: What Manufacturers Should Watch

Europe is not merely the largest gelatin consuming region — at 38–41% of global demand — it is also the region where gelatin quality and compliance standards are setting the pace globally. Regulatory harmonisation across the EU means that a gelatin supplier certified to BRCGS Grade AA and ISO 22000, operating under EU food law, can supply into German, French, Polish, Dutch, and Spanish markets with a single documentation architecture. That simplicity is increasingly valued by procurement teams managing ingredient compliance across multi-country product portfolios.

Supply dynamics in Europe are characterised by a small number of established producers, including major players such as Gelita, Rousselot (Darling Ingredients), PB Leiner, Weishardt, and Brodnica Gelatin as Poland's dedicated porcine gelatin producer. The concentration of European supply means that disruptions to any one producer have market-level consequences; it also means that the qualification of a second European source is prudent risk management for large buyers. Raw material price volatility — driven by shifts in livestock slaughter volumes, disease outbreaks, and logistics bottlenecks — has reinforced this view in recent years.

For buyers thinking about 2027 procurement planning, two dynamics are worth tracking. First, the EU's growing pig meat production (Poland recorded a 7.7% increase in 2024, the strongest growth of any major EU producer) is a positive signal for porcine gelatin raw material availability in Central and Eastern Europe. Second, CSRD obligations already in force for large EU companies extend Scope 3 sustainability reporting into ingredient supply chains; CSDDD — published in 2024 with application phased from 2027 — will further push ingredient buyers toward suppliers who can provide supply chain transparency documentation. Both frameworks favour established, certified European producers over less-documented import sources.

Frequently Asked Questions

How large is the global gelatin market in 2026?

Volume estimates for gelatin (excluding hydrolysed collagen) sit at approximately 441,000–471,000 tonnes annually, based on 2024 data from ChemAnalyst and IMARC Group. Value estimates for conventional gelatin range from $3.6–4.0 billion in 2024, with CAGR projections of 5.5–7.3% depending on scope and methodology. Reports citing higher values ($7–8 billion) typically include hydrolysed collagen and collagen peptide derivatives. Europe accounts for approximately 38–41% of global consumption, the largest regional share across all sources.

Is gelatin considered a clean-label ingredient? 

Yes. Under EU Regulation (EC) No 1333/2008, gelatin is classified as a food ingredient, not a food additive. It carries no E-number and appears on ingredient lists simply as "gelatin." It is non-GMO, minimally processed, and naturally derived from a single source. For non-vegan product formulations, gelatin's clean-label positioning is straightforward, provided the supplier can offer full origin traceability documentation. For vegan or vegetarian products, plant-based alternatives are the appropriate choice.

Is porcine gelatin gaining or losing market share compared to bovine?

Porcine (Type A) gelatin holds approximately 52–57% of the global gelatin market by volume and its position is stable to growing in European and pharmaceutical applications. Its functional advantages — higher Bloom strength, greater gel clarity, shorter extraction time — make it the preferred source for confectionery gelling and pharmaceutical capsule manufacturing. Bovine gelatin retains structural advantages in halal/kosher market segments and in applications where specific regulatory documentation is already built around bovine sources.

What is driving pharmaceutical demand for gelatin in 2026? 

The pharmaceutical gelatin market — valued at $1.3–1.7 billion in 2023–2024 — is growing at approximately 5.5–5.8% CAGR, driven by: rising demand for oral solid dosage forms (hard and soft capsules); expanding OTC supplement consumption; ageing EU and North American populations increasing pharmaceutical volume overall; and the continued growth of nutraceutical gummy and softgel formats. Porcine gelatin held approximately 47% of the pharmaceutical gelatin segment in 2023, with Type A's gelling properties particularly valued in softgel capsule applications.

Why is European origin increasingly valued by gelatin buyers? 

Four converging factors:

(1) Regulatory simplicity — intra-EU sourcing eliminates third-country import documentation and customs risk.

(2) Traceability — European producers with short domestic raw material chains offer simpler, more auditable documentation than intercontinental supply routes.

(3) ESG compliance — CSRD obligations in force from 2024 are pushing Scope 3 reporting into ingredient supply chains; CSDDD, published in 2024 with phased application from 2027, will extend supply chain due diligence requirements further, favouring suppliers who can document sustainability metrics.

(4) Supply security — logistics disruptions in intercontinental shipping routes (Red Sea, Suez, Panama) have reinforced the case for European-origin ingredient sourcing since 2023.

Conclusion

The 2026 gelatin market is not a simple growth story — it is a differentiation story. Demand is growing structurally in pharmaceutical and nutraceutical applications. Porcine gelatin holds its dominant position in European and food-grade applications. Clean-label pressure is real but manageable with the right documentation and origin transparency. And European sourcing is gaining commercial logic that goes beyond proximity, encompassing traceability, ESG compliance, and supply chain resilience.

For food manufacturers planning ingredient strategies for 2027 and beyond, the practical implications of these trends point consistently toward the same question: who supplies your gelatin, where does the raw material come from, and can they document it?

Speak to our team about your supply requirements →

Sources

1. ChemAnalyst — Gelatin Market Report 2024. Global gelatin volume ~441,000 tonnes in 2024; Europe ~36% of global consumption (largest regional share). https://www.chemanalyst.com/industry-report/gelatin-market-3065
2. IMARC Group — Global Gelatin Market Report 2025–2033. Market volume 470,970 tonnes in 2024; CAGR 1.3% (volume-based, conservative, gelatin only); pig skin the largest raw material segment; Europe >39.5% share. https://www.imarcgroup.com/ossein-gelatine-technical-material-market-report
3. Expert Market Research — Global Gelatine Market Report and Forecast 2025–2034. Market value ~$4.04 billion in 2024; CAGR 5.5% through 2034; pork skin and split together account for ~70% of edible gelatin raw materials worldwide. https://www.expertmarketresearch.com/reports/gelatin-market
4. Grand View Research — Gelatin Market Size & Share Analysis, 2030. Market valued at $7.05 billion in 2024 (includes broader scope); projected $13.14 billion by 2030, CAGR 11.1%; Europe 38.3% revenue share; bovine at 35.1% revenue share (revenue differs from volume due to pharmaceutical pricing). https://www.grandviewresearch.com/industry-analysis/gelatin-market-analysis
5. Intel Market Research — Gelatin Market Outlook 2026–2032. Market valued at $3.64 billion in 2024; projected $5.90 billion by 2032, CAGR 7.3%. https://www.intelmarketresearch.com/gelatin-market-21420
6. Fortune Business Insights — Gelatin Market Size, Growth, Trends, Report 2024–2033. Porcine segment at 52.72% global market share in 2026; Europe 41.37% in 2025. https://www.fortunebusinessinsights.com/gelatin-market-107012
7. Coherent Market Insights — Gelatin Market Research 2026. Porcine gelatin 57% global market share; food & beverage segment >40% of total market. https://www.coherentmarketinsights.com/market-insight/gelatin-market-588
8. GM Insights — Pharmaceutical Gelatin Market, 2025–2034. Market valued at $1.3 billion in 2024, projected $2.3 billion by 2034, CAGR 5.8%; bovine 48.4% share of pharmaceutical gelatin; Type A porcine growing at 4.7% CAGR. https://www.gminsights.com/industry-analysis/pharmaceutical-gelatin-market
9. SNS Insider — Pharmaceutical Gelatin Market Size, Trends & Growth 2024–2032. Porcine gelatin held ~47% of pharmaceutical gelatin market share in 2023; market valued at $1.69 billion in 2023; CAGR 5.77% through 2032. https://www.snsinsider.com/reports/pharmaceutical-gelatin-market-2242
10. Rousselot / Darling Ingredients — "What is gelatin made of?" (2024). Confirms gelatin is a food ingredient, not a food additive; does not require an E-number under EU law; describes circular economy sourcing model from animal by-products. https://www.darlingii.com/rousselot/resources/blogs/2024/01/rousselot-what-is-gelatin-made-of
11. European Commission — EU Food Additives Regulation (EC) No 1333/2008 (consolidated 2024). Confirms gelatin is not listed as a food additive requiring an E-number; legal basis for clean-label status in the EU. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:02008R1333-20240602
12. CBI (Centre for the Promotion of Imports) — "What requirements must natural food additives comply with to be allowed on European markets?" (2025). Confirms Corporate Sustainability Due Diligence Directive (CSDDD) published in 2024; impact on ingredient supply chain ESG reporting and Farm-to-Fork alignment. https://www.cbi.eu/market-information/natural-food-additives/what-requirements-must-your-product-comply
13. AHDB / Eurostat — "EU Pork Market: Production and Trade Grow in 2024". Poland pork production up 7.7% in 2024, the strongest rate of increase among major EU producers; context for European porcine gelatin raw material availability. https://ahdb.org.uk/news/eu-pork-market-update-production-and-trade-grow-in-2024-but-fmd-weighs-on-2025-prices